Australia markets closed

Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
2.0800+0.0400 (+1.96%)
At close: 03:04PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 10.08B
Enterprise value 10.90B
Trailing P/E 42.97
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.23
Price/book (mrq)0.49
Enterprise value/revenue 0.24
Enterprise value/EBITDA 0.90

Trading information

Stock price history

Beta (5Y monthly) 0.41
52-week change 3-35.24%
S&P500 52-week change 323.33%
52-week high 33.9100
52-week low 31.9900
50-day moving average 32.3678
200-day moving average 32.8203

Share statistics

Avg vol (3-month) 327.65M
Avg vol (10-day) 331.8M
Shares outstanding 54.94B
Implied shares outstanding 64.94B
Float 81.6B
% held by insiders 168.01%
% held by institutions 13.21%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.11
Forward annual dividend yield 44.98%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 41.53
Payout ratio 412.50%
Dividend date 3N/A
Ex-dividend date 430 May 2023
Last split factor 21.85:1
Last split date 312 Apr 2010

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -1.80%
Operating margin (ttm)-0.82%

Management effectiveness

Return on assets (ttm)-0.47%
Return on equity (ttm)-4.47%

Income statement

Revenue (ttm)43.81B
Revenue per share (ttm)8.56
Quarterly revenue growth (yoy)-20.40%
Gross profit (ttm)N/A
EBITDA -2.07B
Net income avi to common (ttm)-786.84M
Diluted EPS (ttm)-0.1600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)23.45B
Total cash per share (mrq)4.75
Total debt (mrq)23.85B
Total debt/equity (mrq)71.08%
Current ratio (mrq)1.85
Book value per share (mrq)4.16

Cash flow statement

Operating cash flow (ttm)-19.5B
Levered free cash flow (ttm)5.87B